12 results on '"Taneyama Y"'
Search Results
2. Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children
- Author
-
Kato, M, primary, Ishimaru, S, additional, Seki, M, additional, Yoshida, K, additional, Shiraishi, Y, additional, Chiba, K, additional, Kakiuchi, N, additional, Sato, Y, additional, Ueno, H, additional, Tanaka, H, additional, Inukai, T, additional, Tomizawa, D, additional, Hasegawa, D, additional, Osumi, T, additional, Arakawa, Y, additional, Aoki, T, additional, Okuya, M, additional, Kaizu, K, additional, Kato, K, additional, Taneyama, Y, additional, Goto, H, additional, Taki, T, additional, Takagi, M, additional, Sanada, M, additional, Koh, K, additional, Takita, J, additional, Miyano, S, additional, Ogawa, S, additional, Ohara, A, additional, Tsuchida, M, additional, and Manabe, A, additional
- Published
- 2016
- Full Text
- View/download PDF
3. Trametinib for a child with refractory Rosai-Dorfman-Destombes disease harboring a novel somatic mutation in MAP2K1.
- Author
-
Taneyama Y, Morimoto A, Ochiai H, Ando K, Kakuda H, Naruke Y, and Yokoi S
- Abstract
Rosai-Dorfman-Destombes disease (RDD) is a rare histiocytosis characterized by accumulation of S100 + , CD68 + , and CD1a- histiocytes, with emperipolesis. It occurs predominantly in black adolescents and young adults, but rarely in Japanese children. Recently, oncogenic mutations in mitogen-activated protein kinase (MAPK) pathway genes were reported in 30-50% of patients with RDD, and several studies have described treatment of adult patients with MAPK inhibitors. Here, we present the case of a Japanese boy with refractory RDD without signs of cardiofaciocutaneous (CFC) syndrome who harbored MAP2K1 p.Lys59del and responded to trametinib. The patient had lymph node, nasal cavity, kidney, upper respiratory tract, and intracranial involvement. RDD progressed after multi-agent chemotherapy, but responded to trametinib (0.025 mg/kg). Trametinib did not eliminate the mass lesions, but trametinib plus minimal prednisolone (0.1 mg/kg) resulted in a good outcome for more than 15 months, without significant adverse effects. MAP2K1 p.Lys59del has been described as a germline mutation in a patient with CFC syndrome, but not as a somatic mutation in patients with malignancies. Trametinib may be a promising drug for children with RDD that is refractory to multi-agent chemotherapy. Its long-term efficacy and safety alone and in combination with chemotherapy should be investigated., (© 2024. Japanese Society of Hematology.)
- Published
- 2024
- Full Text
- View/download PDF
4. Azacitidine treatment for myeloid leukemia associated with Down syndrome: A nationwide retrospective study in Japan.
- Author
-
Kato S, Nakashima K, Yamato G, Saito S, Taneyama Y, Yamamoto N, Miyamura T, Kato K, Sato Y, Yamada A, Kamiya T, Nishikawa T, Uemura S, Tomizawa D, Moritake H, Terui K, Taga T, and Hasegawa D
- Subjects
- Humans, Male, Female, Retrospective Studies, Japan epidemiology, Child, Preschool, Child, Adolescent, Infant, Adult, Down Syndrome complications, Down Syndrome drug therapy, Azacitidine therapeutic use, Azacitidine adverse effects, Antimetabolites, Antineoplastic therapeutic use, Antimetabolites, Antineoplastic adverse effects, Leukemia, Myeloid drug therapy, Leukemia, Myeloid complications
- Abstract
Hypomethylating agent treatment for myeloid leukemia associated with Down syndrome (ML-DS) has been scarcely reported. Herein, we collected information on azacitidine treatment for ML-DS in Japan. Forty-eight cycles of azacitidine treatment were performed for 12 patients, including 11 relapsed or refractory (R/R) patients. In 40 cycles, azacitidine was used as monotherapy. No azacitidine-related death was observed. One cycle concurrently administered with methotrexate-based intrathecal therapy was discontinued due to toxicities. Only 4 of the 19 cycles given in non-remission achieved complete or partial remission. In conclusion, although most toxicities were acceptable, azacitidine monotherapy might be insufficient for R/R ML-DS cases., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
5. Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms.
- Author
-
Sato T, Yoshida K, Toki T, Kanezaki R, Terui K, Saiki R, Ojima M, Ochi Y, Mizuno S, Yoshihara M, Uechi T, Kenmochi N, Tanaka S, Matsubayashi J, Kisai K, Kudo K, Yuzawa K, Takahashi Y, Tanaka T, Yamamoto Y, Kobayashi A, Kamio T, Sasaki S, Shiraishi Y, Chiba K, Tanaka H, Muramatsu H, Hama A, Hasegawa D, Sato A, Koh K, Karakawa S, Kobayashi M, Hara J, Taneyama Y, Imai C, Hasegawa D, Fujita N, Yoshitomi M, Iwamoto S, Yamato G, Saida S, Kiyokawa N, Deguchi T, Ito M, Matsuo H, Adachi S, Hayashi Y, Taga T, Saito AM, Horibe K, Watanabe K, Tomizawa D, Miyano S, Takahashi S, Ogawa S, and Ito E
- Subjects
- Humans, Male, Female, Leukemoid Reaction genetics, Infant, Child, Preschool, Exome Sequencing, Prognosis, Leukemia, Myeloid genetics, Infant, Newborn, Child, Core Binding Factor Alpha 2 Subunit genetics, Down Syndrome genetics, Down Syndrome complications, Mutation
- Abstract
Abstract: Transient abnormal myelopoiesis (TAM) is a common complication in newborns with Down syndrome (DS). It commonly progresses to myeloid leukemia (ML-DS) after spontaneous regression. In contrast to the favorable prognosis of primary ML-DS, patients with refractory/relapsed ML-DS have poor outcomes. However, the molecular basis for refractoriness and relapse and the full spectrum of driver mutations in ML-DS remain largely unknown. We conducted a genomic profiling study of 143 TAM, 204 ML-DS, and 34 non-DS acute megakaryoblastic leukemia cases, including 39 ML-DS cases analyzed by exome sequencing. Sixteen novel mutational targets were identified in ML-DS samples. Of these, inactivations of IRX1 (16.2%) and ZBTB7A (13.2%) were commonly implicated in the upregulation of the MYC pathway and were potential targets for ML-DS treatment with bromodomain-containing protein 4 inhibitors. Partial tandem duplications of RUNX1 on chromosome 21 were also found, specifically in ML-DS samples (13.7%), presenting its essential role in DS leukemia progression. Finally, in 177 patients with ML-DS treated following the same ML-DS protocol (the Japanese Pediatric Leukemia and Lymphoma Study Group acute myeloid leukemia -D05/D11), CDKN2A, TP53, ZBTB7A, and JAK2 alterations were associated with a poor prognosis. Patients with CDKN2A deletions (n = 7) or TP53 mutations (n = 4) had substantially lower 3-year event-free survival (28.6% vs 90.5%; P < .001; 25.0% vs 89.5%; P < .001) than those without these mutations. These findings considerably change the mutational landscape of ML-DS, provide new insights into the mechanisms of progression from TAM to ML-DS, and help identify new therapeutic targets and strategies for ML-DS., (© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF
6. Genome-wide assessment of genetic risk loci for childhood acute lymphoblastic leukemia in Japanese patients.
- Author
-
Hangai M, Kawaguchi T, Takagi M, Matsuo K, Jeon S, Chiang CWK, Dewan AT, De Smith AJ, Imamura T, Okamoto Y, Saito AM, Deguchi T, Kubo M, Tanaka Y, Ayukawa Y, Hori T, Ohki K, Kiyokawa N, Inukai T, Arakawa Y, Mori M, Hasegawa D, Tomizawa D, Fukushima H, Yuza Y, Noguchi Y, Taneyama Y, Ota S, Goto H, Yanagimachi M, Keino D, Koike K, Toyama D, Nakazawa Y, Nakamura K, Moriwaki K, Sekinaka Y, Morita D, Hirabayashi S, Hosoya Y, Yoshimoto Y, Yoshihara H, Ozawa M, Kobayashi S, Morisaki N, Gyeltshen T, Takahashi O, Okada Y, Matsuda M, Tanaka T, Inazawa J, Takita J, Ishida Y, Ohara A, Metayer C, Wiemels JL, Ma X, Mizutani S, Koh K, Momozawa Y, Horibe K, Matsuda F, Kato M, Manabe A, and Urayama KY
- Subjects
- Child, Humans, Japan epidemiology, Genetic Loci, Genome-Wide Association Study, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics
- Published
- 2024
- Full Text
- View/download PDF
7. Rare TCF3 variants associated with pediatric B cell acute lymphoblastic leukemia.
- Author
-
Miyamoto S, Urayama KY, Arakawa Y, Koh K, Yuza Y, Hasegawa D, Taneyama Y, Noguchi Y, Yanagimachi M, Inukai T, Ota S, Takahashi H, Keino D, Toyama D, Takita J, Tomizawa D, Morio T, Koike K, Moriwaki K, Sato Y, Fujimura J, Morita D, Sekinaka Y, Nakamura K, Sakashita K, Goto H, Manabe A, and Takagi M
- Subjects
- Child, Humans, Genome-Wide Association Study, Oncogene Proteins, Fusion genetics, Transcription Factors genetics, Basic Helix-Loop-Helix Transcription Factors genetics, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma genetics, Burkitt Lymphoma
- Abstract
Germline genetic variants influence development of pediatric B cell acute lymphoblastic leukemia (B-ALL). Genome-wide association studies (GWAS) have identified several pediatric B-ALL susceptibility loci. IKZF1 and PAX5 , transcription factors involved in B cell development, have been reported as susceptibility genes for B-ALL development. Therefore, we hypothesized that rare variants of genes involved in B cell development would be candidate susceptibility loci for pediatric B-ALL. Thus, we sequenced TCF3 , a key transcription factor gene involving in B cell development. Saliva DNA from 527 pediatric patients with pediatric B-ALL in remission who were registered with the Tokyo Children's Cancer Study Group (TCCSG) were examined. As a TCF3 gene-based evaluation, the numbers of rare deleterious germline TCF3 sequence variants in patients with pediatric B-ALL were compared with those in cancer-free individuals using data in public databases. As a TCF3 single-variant evaluation, the frequencies of rare deleterious germline TCF3 sequence variants in patients with pediatric B-ALL were also compared with those in control data. TCF3 gene-based analysis revealed significant associations between rare deleterious variants and pediatric B-ALL development. In addition, TCF3 variant-based analysis showed particularly strong association between variant rs372168347 (three in 521 TCCSG and three in the 15780 gnomAD whole genome analysis cohort, p = 0.0006) and pediatric B-ALL development. TCF3 variants are known to influence B cell maturation and may increase the risk of preleukemic clone emergence.
- Published
- 2024
- Full Text
- View/download PDF
8. Reappraisal of the Genus Exsudoporus ( Boletaceae ) Worldwide Based on Multi-Gene Phylogeny, Morphology and Biogeography, and Insights on Amoenoboletus .
- Author
-
Biketova AY, Gelardi M, Smith ME, Simonini G, Healy RA, Taneyama Y, Vasquez G, Kovács Á, Nagy LG, Wasser SP, Peintner U, Nevo E, Bunyard BA, and Vizzini A
- Abstract
The boletoid genera Butyriboletus and Exsudoporus have recently been suggested by some researchers to constitute a single genus, and Exsudoporus was merged into Butyriboletus as a later synonym. However, no convincing arguments have yet provided significant evidence for this congeneric placement. In this study, we analyze material from Exsudoporus species and closely related taxa to assess taxonomic and phylogenetic boundaries between these genera and to clarify species delimitation within Exsudoporus . Outcomes from a multilocus phylogenetic analysis (ITS, nrLSU, tef1-α and rpb2 ) clearly resolve Exsudoporus as a monophyletic, homogenous and independent genus that is sister to Butyriboletus . An accurate morphological description, comprehensive sampling, type studies, line drawings and a historical overview on the nomenclatural issues of the type species E. permagnificus are provided. Furthermore, this species is documented for the first time from Israel in association with Quercus calliprinos . The previously described North American species Exsudoporus frostii and E. floridanus are molecularly confirmed as representatives of Exsudoporus , and E. floridanus is epitypified. The eastern Asian species Leccinum rubrum is assigned here to Exsudoporus based on molecular evidence, and a new combination is proposed. Sequence data from the original material of the Japanese Boletus kermesinus were generated, and its conspecificity with L. rubrum is inferred as formerly presumed based on morphology. Four additional cryptic species from North and Central America previously misdetermined as either B. frostii or B. floridanus are phylogenetically placed but remain undescribed due to the paucity of available material. Boletus weberi (syn. B. pseudofrostii ) and Xerocomus cf. mcrobbii cluster outside of Exsudoporus and are herein assigned to the recently described genus Amoenoboletus . Biogeographic distribution patterns are elucidated, and a dichotomous key to all known species of Exsudoporus worldwide is presented.
- Published
- 2022
- Full Text
- View/download PDF
9. An international retrospective study for tolerability of 6-mercaptopurine on NUDT15 bi-allelic variants in children with acute lymphoblastic leukemia.
- Author
-
Tanaka Y, Yeoh AEJ, Moriyama T, Li CK, Kudo K, Arakawa Y, Buaboonnam J, Zhang H, Liu HC, Ariffin H, Chen Z, Kham SKY, Nishii R, Hasegawa D, Fujimura J, Keino D, Kondoh K, Sato A, Ueda T, Yamamoto M, Taneyama Y, Hino M, Takagi M, Ohara A, Ito E, Koh K, Hori H, Manabe A, Yang JJ, and Kato M
- Subjects
- Alleles, Child, Humans, Pyrophosphatases genetics, Retrospective Studies, Mercaptopurine adverse effects, Precursor Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics
- Published
- 2021
- Full Text
- View/download PDF
10. Regional evaluation of childhood acute lymphoblastic leukemia genetic susceptibility loci among Japanese.
- Author
-
Urayama KY, Takagi M, Kawaguchi T, Matsuo K, Tanaka Y, Ayukawa Y, Arakawa Y, Hasegawa D, Yuza Y, Kaneko T, Noguchi Y, Taneyama Y, Ota S, Inukai T, Yanagimachi M, Keino D, Koike K, Toyama D, Nakazawa Y, Kurosawa H, Nakamura K, Moriwaki K, Goto H, Sekinaka Y, Morita D, Kato M, Takita J, Tanaka T, Inazawa J, Koh K, Ishida Y, Ohara A, Mizutani S, Matsuda F, and Manabe A
- Subjects
- Adolescent, Child, Child, Preschool, DNA-Binding Proteins genetics, Female, Genetic Loci, Genome-Wide Association Study, Humans, Ikaros Transcription Factor genetics, Infant, Infant, Newborn, Japan, Linkage Disequilibrium, Male, Phosphotransferases (Alcohol Group Acceptor) genetics, Polymorphism, Single Nucleotide, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics, Transcription Factors genetics, Young Adult, Asian People genetics, Genetic Predisposition to Disease, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology
- Abstract
Genome-wide association studies (GWAS) performed mostly in populations of European and Hispanic ancestry have confirmed an inherited genetic basis for childhood acute lymphoblastic leukemia (ALL), but these associations are less clear in other races/ethnicities. DNA samples from ALL patients (aged 0-19 years) previously enrolled onto a Tokyo Children's Cancer Study Group trial were collected during 2013-2015, and underwent single nucleotide polymorphism (SNP) microarray genotyping resulting in 527 B-cell ALL for analysis. Cases and control data for 3,882 samples from the Nagahama Study Group and Aichi Cancer Center Study were combined, and association analyses across 10 previous GWAS-identified regions were performed after targeted SNP imputation. Linkage disequilibrium (LD) patterns in Japanese and other populations were evaluated using the varLD score based on 1000 Genomes data. Risk associations for ARID5B (rs10821936, OR = 1.84, P = 6 × 10
-17 ) and PIP4K2A (rs7088318, OR = 0.76, P = 2 × 10-4 ) directly transferred to Japanese, and the IKZF1 association was detected by an alternate SNP (rs1451367, OR = 1.52, P = 2 × 10-6 ). Marked regional LD differences between Japanese and Europeans was observed for most of the remaining loci for which associations did not transfer, including CEBPE, CDKN2A, CDKN2B, and ELK3. This study represents a first step towards characterizing the role of genetic susceptibility in childhood ALL risk in Japanese.- Published
- 2018
- Full Text
- View/download PDF
11. [Congenital leukemia showing lineage switch following induction chemotherapy and attaining long-term remission after HLA-haploidentical stem cell transplantation].
- Author
-
Furudate K, Okimoto Y, Ando K, Taneyama Y, Ochiai H, and Kakuda H
- Subjects
- Female, Haplotypes, Humans, Induction Chemotherapy, Infant, Newborn, Leukemia, Monocytic, Acute pathology, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma congenital, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma immunology, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma pathology, Recurrence, Remission Induction, Time Factors, HLA Antigens immunology, Leukemia, Monocytic, Acute therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy, Stem Cell Transplantation
- Abstract
Congenital leukemia is a rare subgroup of childhood leukemia. Lineage switches in leukemic cells are relatively rare events, which have been occasionally reported in congenital leukemia. To the best of our knowledge, the survival of congenital leukemia patients with lineage switch has not been previously documented. This lack of documentation may be attributable to extremely poor prognosis of these patients. We describe a case of a newborn female with initial diagnosis of MLL-AF4 positive B-precursor acute lymphoblastic leukemia, who developed lineage switch to acute monocytic leukemia following the induction therapy. Although morphological remission was temporary, she received an HLA-haploidentical bone marrow transplant from her father with non-remission status because of an early relapse at the age of 4 months. Despite many difficulties such as graft-versus-host disease, growth impairment, and psychomotor retardation, she remained in remission for 3 years and 7 months after the transplant. This successful outcome suggests that the graft-versus-leukemia effect was potentially accomplished in the patient. Taken together, early HLA-haploidentical stem cell transplant following remission is required for congenital leukemia patients with lineage switch, and it may be an effective alternative for refractory patients.
- Published
- 2017
- Full Text
- View/download PDF
12. Histological features of primary tumors after induction or high-dose chemotherapy in high-risk neuroblastoma.
- Author
-
Hishiki T, Horie H, Higashimoto Y, Yotsumoto K, Komatsu S, Okimoto Y, Kakuda H, Taneyama Y, Saito T, Terui K, Mitsunaga T, Nakata M, Ochiai H, Hino M, Ando K, Yoshida H, and Iwai J
- Subjects
- 3-Iodobenzylguanidine, Child, Child, Preschool, Female, Follow-Up Studies, Humans, Infant, Japan, Male, Neuroblastoma surgery, Radionuclide Imaging, Radiopharmaceuticals, Retrospective Studies, Second-Look Surgery methods, Survival Analysis, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Induction Chemotherapy methods, Neuroblastoma diagnostic imaging, Neuroblastoma drug therapy
- Abstract
Purpose: In the recent years in Japan, an increasing number of patients with neuroblastoma (NB) are being treated by the "delayed local treatment (DL)" policy, undergoing surgery after the completion of high-dose chemotherapy with hematopoietic stem cell rescue (HDC). We reviewed the histopathological findings of second-look operations, including those of patients treated with DL., Patients: From 1998 to 2013, 26 patients with high-risk NB underwent radical operation following chemotherapy. Surgery was performed after induction chemotherapy in 17 cases (standard; STD), whereas 9 cases completed induction chemotherapy and HDC before undergoing tumor resection (DL). The amount of necrosis and the degree of differentiation within the post-treatment tumor were assessed., Results: Eighty-eight percent of the tumors showed necrosis in more than 1/3 of the specimen. Two DL cases showed complete disappearance of viable tumor cells. Amount of necrosis did not affect the prognosis of the patient. Tumors with immature, poorly differentiated phenotypes showed an extremely aggressive thereafter. Though not statistically proven, (123)I-MIBG (metaiodobenzylguanidine) uptake may be correlated with the amount of viable cells remaining within the tumor, but not with the degree of differentiation., Conclusions: Our results support the previous reports advocating that tumors that sustain unfavorable histology after chemotherapy behave aggressively thereafter.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.